We just lately printed 10 Shares Left Behind Amid Wall Avenue Cheer. Soleno Therapeutics Inc. (NASDAQ:SLNO) is among the worst-performing shares on Wednesday.
Soleno Therapeutics prolonged its dropping streak to a fifth consecutive day on Wednesday, slashing 26.59 % to shut at $46.87 apiece as buyers appeared to have priced in a powerful earnings efficiency within the third quarter of the yr.
The maker of the primary and solely FDA-approved drug for hyperphagia stated in an up to date report that it swung to a internet revenue of $26 million, or a 134 % enchancment from the $76.6 million internet loss in the identical interval final yr. It additionally incurred revenues of $66 million in the course of the quarter.
kurhan / shutterstock.com
“Our robust third quarter outcomes replicate rising consciousness of the compelling efficacy and security profile of Vykat XR throughout the PWS neighborhood,” stated Soleno Therapeutics Inc. (NASDAQ:SLNO) Chairman and CEO Anish Bhatnagar.
“As the primary and solely FDA-approved remedy to deal with the hallmark symptom of PWS—hyperphagia—in sufferers 4 years and older, Vykat XR can supply a brand new choice to this fragile and complicated affected person inhabitants that usually suffers from a large number of great co-morbidities … and we’re working tirelessly to make it as broadly accessible as potential,” he added.
Whereas we acknowledge the potential of SLNO as an funding, our conviction lies within the perception that some AI shares maintain higher promise for delivering increased returns and have restricted draw back danger. In case you are searching for a particularly low-cost AI inventory that can be a serious beneficiary of Trump tariffs and onshoring, see our free report on the greatest short-term AI inventory.
READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.
Disclosure: None. This text is initially printed at Insider Monkey.